Bullfrog AI Holdings, Inc. (BFRG)
BFRGNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$0.5800
+0.0288 (+5.22%) today
At the close, Nov 10, 4:00 PM ET. After hours $0.5703 -4.79%
- Market cap
- $11.11m
- P/E
- –
- EPS, last 4 quarters
- $-0.4600
- Dividend yield
- –
- Day range
- $0.5400 to $0.5900
- 52-week range
- $0.4251 to $1.96
- Average volume
- 6.74m
- Previous close
- $0.5512
Earnings
next estimate $-0.0900Next report Nov 13, 2026
Sep 2025
–
Dec 2025
–
Mar 2026
–
Jun 2026
+36.4%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $83.0k | – | – | $215.0k |
| Gross profit | $15.0k | – | – | $107.0k |
| Operating income | -$1.57m | -$1.50m | -$1.61m | -$1.42m |
| Net income | -$1.55m | -$1.48m | -$1.59m | -$1.37m |
News
8 latest- Is Bullfrog AI Holdings Inc. (BFRG) Outperforming Other Medical Stocks This Year?Zacks · Sep 24, 2026
- Nutex Health Soars 21% After Hours On Revenue Surge; Biotech Peers Join Tuesday Gainers RTTNews · Nov 18, 2025
- ZCMD, ABCL, VOR, IXHL, OVID, BFRG Rally After Hours On Clinical Momentum And Recent Updates RTTNews · Oct 2, 2025
- BullFrog AI Launches bfLEAP™ to Revolutionize Drug Discovery and Improve Clinical Trial Success RatesQuiver Quantitative · Jul 22, 2025
- BullFrog AI Holdings, Inc. Announces Dr. Juan Felipe Beltrán as Featured Speaker at XTalks Webinar on AI in BioinformaticsQuiver Quantitative · Jun 20, 2025
- BullFrog AI Holdings, Inc. Announces Strategic Collaboration with Sygnature Discovery to Enhance Drug Development CapabilitiesQuiver Quantitative · Jun 12, 2025
- Insider Sale: Chief Executive Officer of $BFRG Sells 27,958 SharesQuiver Quantitative · Apr 3, 2025
- Can BullFrog AI Continue to Leap Higher?Zacks · Feb 11, 2025
The company
BullFrog AI harnesses artificial intelligence and machine learning to advance pharmaceutical R&D and drug target discovery, providing AI-accelerated outputs that are optimized and human-validated. BullFrog AI operates through three complementary capabilities, deployable independently or as a combined platform: bfPREP for biology-aware data harmonization, bfLEAP® for causal AI analytics and patient subgroup discovery, and bfARENAS for structured, auditable decision support. The common thread across all three: every output is traceable, every analytical decision is logged, and every recommendation is designed to be reviewed and validated by the scientific team before it drives a decision.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- bullfrogai.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.